Last updated: August 1, 2026
Novo Nordisk Inc. v. Rio Biopharmaceuticals, Inc. 1:24-cv-00330: Litigation Summary, Claims at Issue, and Likely Exclusivity/Market Impact
Executive summary:
Novo Nordisk Inc. v. Rio Biopharmaceuticals, Inc. (Docket 1:24-cv-00330) is a US patent infringement case filed in 2024 in which Novo Nordisk asserts infringement against Rio Biopharmaceuticals. The case posture, asserted patent numbers, claim scope, and any Paragraph IV or Orange Book framework can’t be determined from the provided input alone. Without the complaint/claims list, the court, filing date, asserted patents, and any settlement or injunction history, a complete litigation summary and infringement/validity analysis would require case-document facts that are not included here.
What does Novo Nordisk allege in Novo Nordisk v. Rio Biopharmaceuticals 1:24-cv-00330?
Featured snippet answer: The specific allegations (asserted patents, accused products, and infringement theories) are not available in the provided information.
Which patents are asserted in 1:24-cv-00330?
No asserted patent numbers or titles are provided in the prompt.
What product(s) does Rio Biopharmaceuticals allegedly infringe?
No accused drug names, dosage forms, or packaging identifiers are provided in the prompt.
What infringement theory is pleaded (direct, induced, contributory)?
No claim-level allegations are provided in the prompt.
Which claims are being targeted: method-of-use, composition, or formulation patents?
Featured snippet answer: Claim type and scope cannot be determined from the provided input.
Are method-of-use claims asserted (e.g., specific dosing regimen or therapeutic indication)?
Not specified.
Are composition claims asserted (active ingredient + excipients, salts, polymorphs)?
Not specified.
Are manufacturing or process claims asserted?
Not specified.
What procedural posture does the case have in 1:24-cv-00330?
Featured snippet answer: The case stage (motion practice, Markman status, trial scheduling, or dispositive rulings) is not included in the prompt.
Has the court issued claim construction (Markman) orders?
Not specified.
Have there been motions to dismiss, transfer, or compel?
Not specified.
Have there been infringement/validity summary-judgment motions?
Not specified.
When do patents asserted in 1:24-cv-00330 expire, and how does that affect leverage?
Featured snippet answer: Patent expiration dates cannot be analyzed without the asserted patent numbers.
How to map patent term to enforcement leverage
A term map requires the specific patent family members and their earliest non-provisional filing dates and any PTA/terminal disclaimers, which are not provided.
How many different patent families are at issue
Not specified.
What is the Orange Book and FDA exclusivity relevance to Novo Nordisk v. Rio Biopharmaceuticals?
Featured snippet answer: Orange Book status (listed drug, listed patents, and exclusivity code) cannot be determined without identifying the underlying FDA product and asserted patent numbers.
Is this an ANDA or 505(b)(2)-related dispute?
Not specified.
Is the case tied to Paragraph IV certifications?
Not specified.
Does the dispute involve pediatric exclusivity or 3-year new chemical entity exclusivity?
Not specified.
Are there biosimilar or interchangeability issues in 1:24-cv-00330?
Featured snippet answer: Biosimilar or interchangeability frameworks cannot be assessed without knowing whether the accused product is a biologic and without the asserted claims or FDA pathway.
Is Rio challenging a reference biologic?
Not specified.
Is there a BLA/351(k) or interchangeability designation angle?
Not specified.
What has Novo Nordisk sought: injunction, damages, or declaratory relief?
Featured snippet answer: The remedies sought are not provided.
Is Novo Nordisk seeking a preliminary injunction?
Not specified.
Is Novo Nordisk seeking permanent injunctive relief and enhanced damages?
Not specified.
Is there a request for attorneys’ fees under 35 U.S.C. § 285?
Not specified.
How strong is the patent estate in this dispute based on the pleadings?
Featured snippet answer: A strength assessment requires the asserted claims and their prosecution history, which are not provided.
Expected validity arguments
Not specified.
Expected infringement rebuttals
Not specified.
Expected design-around pathways (salt/polymorph, device, regimen, excipient)
Not specified.
What generic entry risks exist for the accused product if Novo wins 1:24-cv-00330?
Featured snippet answer: Entry risks cannot be quantified without identifying the FDA pathway, the approval status of the accused product, and the patents at issue.
Could an injunction block launch immediately?
Not specified.
Could partial invalidation narrow the design space instead of fully stopping entry?
Not specified.
What settlement signals are present in the docket for 1:24-cv-00330?
Featured snippet answer: Settlement terms, stipulations, or dismissals are not provided in the prompt.
Was there a stipulation of dismissal or covenant not to sue?
Not specified.
Any court-ordered stay pending appeal or reexamination?
Not specified.
Which companies are involved beyond Novo Nordisk and Rio Biopharmaceuticals in 1:24-cv-00330?
Featured snippet answer: The prompt does not include named co-defendants, ANDA filers, generic distributors, or manufacturer suppliers.
Are there contract manufacturers or distributors named as defendants?
Not specified.
How does this case compare with other Novo Nordisk v. generic/biosimilar litigation?
Featured snippet answer: Direct comparisons require the specific asserted patents and drug/API at issue.
Comparability factors
Not specified.
Key Takeaways
- The provided input contains only the case caption and docket number. It does not include asserted patents, accused products, court, filing date, or procedural milestones.
- A complete litigation summary and infringement/validity analysis is not possible without those case-document facts.
- Any exclusivity and Orange Book relevance analysis requires identification of the FDA-listed drug and the specific patents asserted, which are not included.
FAQs
- What court and judge are assigned to Novo Nordisk Inc. v. Rio Biopharmaceuticals (1:24-cv-00330)?
- Which specific patents does Novo Nordisk assert in 1:24-cv-00330?
- What accused drug or formulation is at issue in the complaint?
- Does 1:24-cv-00330 involve a Paragraph IV ANDA certification or a 351(k) biosimilar pathway?
- Has the docket in 1:24-cv-00330 reached Markman claim construction or issued any substantive rulings?
References
- Docket: Novo Nordisk Inc. v. Rio Biopharmaceuticals, Inc., 1:24-cv-00330. (Source: provided case citation only.)
